CHALFONT ST GILES, England--(BUSINESS WIRE)--June 5, 2006--GE Healthcare, a division of the General Electric Company (NYSE:GE - News), announced today that it has initiated a first-in-man clinical study designed to validate information provided by a molecular imaging agent in evaluating the extent and nature of cancer. Specifically, this proprietary positron emission tomography (PET) agent has a biological mechanism to track the process of angiogenesis, the formation of new blood vessels in the body.
